Structural and functional insights into aldosterone synthase interaction with its redox partner protein adrenodoxin.
CYP11B2
adrenodoxin
aldosterone
cytochrome P450
hypertension
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
Historique:
received:
19
04
2021
revised:
12
05
2021
accepted:
14
05
2021
pubmed:
21
5
2021
medline:
1
9
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
Aldosterone is the major mineralocorticoid in the human body controlling blood pressure and salt homeostasis. Overproduction of aldosterone leads to primary aldosteronism, which is the most common form of secondary hypertension with limited treatment options. Production of aldosterone by cytochrome P450 11B2 (CYP11B2, aldosterone synthase) requires two reduction events with the electrons delivered by the iron/sulfur protein adrenodoxin. Very limited information is available about the structural and functional basis of adrenodoxin/CYP11B2 interaction, which impedes the development of new treatment options for primary aldosteronism. A systematic study was carried out to determine if adrenodoxin interaction with CYP11B2 might also have an allosteric component in addition to electron transfer. Indeed, local increases in adrenodoxin concentration promote binding of the substrate 11-deoxycorticosterone and the inhibitor osilodrostat (LCI699) in the active site-over 17 Å away-as well as enhance the inhibitory effect of this latter drug. The CYP11B2 structure in complex with adrenodoxin identified specific residues at the protein-protein interface interacting via five salt bridges and four hydrogen bonds. Comparisons with cholesterol-metabolizing CYP11A1 and cortisol-producing CYP11B1, which also bind adrenodoxin, revealed substantial structural differences in these regions. The structural and functional differences between different P450 interactions with adrenodoxin may provide valuable clues for an orthogonal treatment approach for primary aldosteronism by specifically targeting the interaction between CYP11B2 and adrenodoxin.
Identifiants
pubmed: 34015331
pii: S0021-9258(21)00587-1
doi: 10.1016/j.jbc.2021.100794
pmc: PMC8215293
pii:
doi:
Substances chimiques
Adrenodoxin
12687-22-8
Cytochrome P-450 CYP11B2
EC 1.14.15.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
100794Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
J Biol Chem. 2019 Aug 30;294(35):12975-12991
pubmed: 31296661
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Med Chem. 1991 Feb;34(2):725-36
pubmed: 1825337
J Biol Chem. 1997 Feb 21;272(8):4883-8
pubmed: 9030546
J Clin Endocrinol Metab. 2010 Feb;95(2):779-88
pubmed: 20089618
Mol Endocrinol. 2013 Feb;27(2):315-24
pubmed: 23322723
J Comput Aided Mol Des. 2007 Aug;21(8):455-71
pubmed: 17646925
Hypertension. 2010 Nov;56(5):831-8
pubmed: 20837883
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1933-E1940
pubmed: 28228528
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2256-68
pubmed: 15572779
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4552-6
pubmed: 8506298
Biochim Biophys Acta. 2007 Mar;1770(3):330-44
pubmed: 16978787
Biol Chem. 2002 Oct;383(10):1537-51
pubmed: 12452430
J Biol Chem. 2011 Feb 18;286(7):5607-13
pubmed: 21159775
Biochemistry. 2020 Apr 21;59(15):1537-1548
pubmed: 32259445
Biochemistry. 2002 Jul 2;41(26):8310-20
pubmed: 12081479
J Steroid Biochem Mol Biol. 2018 Jul;181:63-72
pubmed: 29548669
J Steroid Biochem Mol Biol. 2013 Jul;136:47-53
pubmed: 23165146
Circulation. 2004 Sep 14;110(11):e296-7
pubmed: 15364820
IUBMB Life. 2012 Jun;64(6):506-12
pubmed: 22556163
J Inorg Biochem. 2002 Sep 20;91(4):644-54
pubmed: 12237230
Chin Med J (Engl). 2010 May 20;123(10):1264-8
pubmed: 20529578
Steroids. 1997 Jan;62(1):124-7
pubmed: 9029726
Lancet Diabetes Endocrinol. 2018 Jan;6(1):41-50
pubmed: 29129575
J Endocrinol. 2005 Jul;186(1):1-20
pubmed: 16002531
Mol Cell Endocrinol. 2017 Feb 5;441:55-61
pubmed: 27815210
J Med Chem. 2014 Jun 26;57(12):5011-22
pubmed: 24422519
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Biol Chem. 1976 Dec 10;251(23):7545-50
pubmed: 12171
Drug Metab Dispos. 2018 Sep;46(9):1329-1337
pubmed: 29991575
J Steroid Biochem Mol Biol. 2019 Nov;194:105439
pubmed: 31362062
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Biochem Biophys Res Commun. 1977 Jul 25;77(2):804-9
pubmed: 561606
J Steroid Biochem Mol Biol. 2015 Jul;151:38-51
pubmed: 25465475
Clin Endocrinol (Oxf). 2009 Mar;70(3):363-71
pubmed: 18710464
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8516-20
pubmed: 2236061
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Drugs. 2020 Apr;80(5):495-500
pubmed: 32141023
Hypertension. 2021 Jul 12;:HYPERTENSIONAHA12117615
pubmed: 34247511
J Biol Chem. 2019 Jan 11;294(2):453-460
pubmed: 30425102
Biochemistry. 2017 May 2;56(17):2282-2293
pubmed: 28355486
Nat Rev Drug Discov. 2016 Aug;15(8):533-50
pubmed: 27050677
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10139-43
pubmed: 21636783
J Mol Biol. 2013 Nov 15;425(22):4353-65
pubmed: 23856620
J Biol Chem. 2001 Jan 26;276(4):2786-9
pubmed: 11053423